BioTime to Present at Two Upcoming Investor Conferences
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 6, 2016--
BioTime, Inc. (NYSE MKT: BTX), a clinical stage biotechnology company
with a focus on pluripotent stem cell technology, today announced that it
will be presenting at the following investor conferences:
Gateway Conference at the Four Seasons Hotel, San Francisco,
Wednesday, September 7, 2016, at 11:00am ET (8:00am PT)
18th Annual Rodman & Renshaw Global Investor Conference at
the Lotte New York Palace Hotel, New York City, Tuesday, September 13,
2016, at 3:50pm ET (12:50pm PT)
Attendance at both conferences is by invitation only. BioTime’s
management will provide a corporate overview as well as an update on its
product development. Both presentations will be webcast live and
available for replay at the “Events & Presentations” page of the
“Investors & Media” section on BioTime’s website at http://www.biotimeinc.com.
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what we
believe to be the world’s premier collection of pluripotent cell assets.
The foundation of our core therapeutic technology platform is
pluripotent cells that are capable of becoming any of the cell types in
the human body. Pluripotent cells have potential application in many
areas of medicine with large unmet patient needs, including various
age-related degenerative diseases and degenerative conditions for which
there presently are no cures. Unlike pharmaceuticals that require a
molecular target, therapeutic strategies based on the use of pluripotent
cells are generally aimed at regenerating or replacing affected cells
and tissues, and therefore may have broader applicability than
In addition to the development of therapeutics, BioTime’s research and
other activities have resulted, over time, in the creation of other
subsidiaries that address other non-therapeutic market opportunities
such as cancer diagnostics, drug development and cell research products,
and mobile health software applications.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter,
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160906005542/en/
Source: BioTime, Inc.
Dan L. Lawrence, 510-775-0510
EVC Group, Inc.
Michael Polyviou, 646-445-4800
Gotham Communications, LLC
Bill Douglass, 646-504-0890